Global Market for Oral Cancer Treatments Expected to Reach $2.72 Billion by 2030 with 4.8% CAGR Growth
Allied Market Research published a report, titled, “Oral Cancer Treatment Market by Treatment (Chemotherapy, Immunotherapy, and Targeted Therapy), Age Group (30-49, 50-69 and 70<), and End User (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Store): Global Opportunity Analysis and Industry Forecast, 2021–2030.” According to the report, the global oral cancer treatment market was valued at $1.71 billion 2020, and is expected to reach $2.72 billion by 2030, witnessing a CAGR of 4.8% from 2021 to 2030.
Oral cancers are part of a group of cancers commonly referred to as head and neck cancers, and of all head and neck cancers, they comprise about 85% of that category. Furthermore, oral cancer accounts for approximately three 3% of all cancers diagnosed annually in the U.S, or about 53,000 new cases each year. In addition, oral cancer most often occurs in people over the age of 40 and affects more than twice as many men as women. Most oral cancers are related to tobacco use, alcohol use (or both), or infection by the human papilloma virus (HPV).
𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 @ https://www.alliedmarketresearch.com/purchase-enquiry/15272
𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
TEVA PHARMACEUTICALS INDUSTRIES LTD, MERCK & CO. INC., CIPLA INC., ELI-LILLY, FRESENIUS KABI AG, BRISTOL MAYERS SQUIBB COMPANY, SANOFI S.A, F-HOFFMANN-LA-ROCHE, VIATRIS INC. (MYLAN N.V), INTAS PHARMACEUTICALS LTD.
Drivers, restraints, and opportunities
Rise in prevalence of oral cancer and surge in government expenditure on healthcare drive the growth of the global oral cancer treatment market. However, adverse effects regarding usage of cancer drugs hinder the market growth. On the other hand, rise in number of pipeline drugs and untapped potential in emerging countries create new opportunities in the coming years.
Covid-19 Scenario
- Dentists play a crucial role in detection of oral cancer through screening of oral cavities. The closure of dental clinics during the lockdown led to reduced detection activities, which in turn, impacted the treatment measures.
- There has been postponement of elective surgeries during the pandemic to prevent cross-contamination. Surgeries were conducted only for malignant or potentially malignant lesions only. Else, surgeries were postponed.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.alliedmarketresearch.com/request-sample/15272
The hospital pharmacies segment to continue its dominance during the forecast period
Based on end user, the hospital pharmacies segment held the highest share in 2020, accounting for more than half of the global oral cancer treatment market, and is projected to continue its dominance in terms of revenue during the forecast period. Moreover, this segment is expected to portray the highest CAGR of 4.9% from 2021 to 2030. As patients are admitted to hospitals for chemotherapy and other treatments, it becomes easier for them to get the medicines prescribed from hospital pharmacies as compared to other stores. This leads to the highest revenue generation. The research also analyzes the segments including drug stores & retail pharmacies and online stores.
The chemotherapy segment to continue its leadership status during the forecast period
Based on drug type, the chemotherapy segment accounted for the highest share in 2020, contributing to around two-thirds of the global oral cancer treatment market, and is estimated to continue its leadership status during the forecast period. This type of treatment is provided every day for the course of six weeks according to the size of the cancer and its spread. This results in the highest revenue generation. However, the targeted therapy segment is expected to witness the largest CAGR of 5.5% from 2021 to 2030.
Drivers, restraints, and opportunities
Rise in prevalence of oral cancer and surge in government expenditure on healthcare drive the growth of the global oral cancer treatment market. However, adverse effects regarding usage of cancer drugs hinder the market growth. On the other hand, rise in number of pipeline drugs and untapped potential in emerging countries create new opportunities in the coming years.
𝐕𝐀𝐋𝐔𝐄 𝐏𝐑𝐎𝐏𝐎𝐒𝐈𝐓𝐈𝐎𝐍𝐒 𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐓𝐎 𝐓𝐇𝐄 𝐑𝐄𝐏𝐎𝐑𝐓:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
𝐀𝐛𝐨𝐮𝐭 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
𝐂𝐨𝐧𝐭𝐚𝐜𝐭
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Editor Details
-
Company:
- The Wire Times
